| Case Report Online Published: 05 Jul 2025 | ||||||||||||||||||||||||||||||
Case Rep Ser Med. 2025; 2(3): 45-48 Pediatric Covid-19 in a child with neurofibromatosis type 1 Ali Ghasemi Zadeh.
| ||||||||||||||||||||||||||||||
Introduction
Neurofibromatosis type 1 (NF1) is a relatively common genetic disorder, affecting roughly 1 in 3,000 individuals worldwide [1]. It is characterized by the development of benign tumors called neurofibromas and a range of skin and neurological manifestations [2]. The root cause of NF1 lies in mutations of the NF1 gene on chromosome 17, which disrupts the production of neurofibromin, a crucial protein involved in regulating cell growth. Diagnostic hallmarks of NF1 include the presence of café-aulait spots (flat, hyperpigmented skin markings) and Lisch nodules (benign iris hamartomas) [3]. Other clinical features include freckling in atypical locations and an increased susceptibility to certain tumors, such as malignant peripheral nerve sheath tumors or optic pathway gliomas [4]. Cognitive challenges, including learning difficulties and attention deficit hyperactivity disorder, are also frequently associated with NF1 [5]. The variable expression of NF1, with symptoms ranging in severity, poses challenges for both diagnosis and management. Currently, there is no cure, so treatment focuses on managing symptoms, vigilant monitoring for orthopedic and oncological complications, and providing supportive therapies to enhance quality of life [6]. Ongoing research is critical for unraveling the intricacies of NF1 and identifying potential therapeutic interventions.The emergence of COVID-19, caused by the novel SARS-CoV-2 coronavirus, in late 2019 rapidly escalated into a global pandemic. Originating in Wuhan, China, the virus spread quickly from an initial cluster of cases linked to a seafood market [7]. Recognizing the severity and global reach of the outbreak, the World Health Organization declared a Public Health Emergency of International Concern in January 2020, followed by a pandemic designation in March 2020 [8]. The primary mode of transmission for SARS-CoV-2 is via respiratory droplets expelled during coughing, sneezing, speaking, or breathing. Transmission can also occur through contact with contaminated surfaces, followed by touching the face [9]. COVID-19 presents with a diverse range of symptoms, from mild respiratory illness to severe pneumonia and, in some cases, death [10]. Asymptomatic individuals also play a significant role in transmission, complicating efforts to contain the virus [11].Global responses to the COVID-19 pandemic included the implementation of strategies aimed at slowing transmission, such as lockdowns, travel restrictions, mask mandates, and social distancing guidelines [12]. The pandemic placed unprecedented strain on healthcare systems globally and brought into sharp focus existing disparities in access to healthcare. The economic impact of COVID-19 has been substantial, resulting in recessions in many countries, widespread job losses, and significant shifts in work environments, including the rise of remote work [13]. The current approach to managing COVID-19 involves a multifaceted strategy encompassing vaccination campaigns, booster doses, and public health measures designed to mitigate outbreaks while enabling a return to normal life [14].
Case Presentation
An 8-year-old boy presented to the pediatric emergency department with respiratory distress and fever. His symptoms had begun 3 days prior, starting with mild pharyngitis and fatigue. Within 24 hours, he developed a fever reaching a high of 39.2°C and a cough progressing from non-productive to productive, producing white sputum. He also reported decreased oral intake, lethargy, and rhinorrhea. Acetaminophen provided only partial relief from his fever. His parents reported no known COVID-19 exposure, although a recent upsurge in respiratory illnesses had been noted at his school.The patient’s medical history included a diagnosis of NF1 at age 4, characterized by numerous café-au-lait spots, axillary freckling (consistent with Crowe’s sign), identifiable Lisch nodules, and mild scoliosis. His father also has NF1; his mother is unaffected. He had no known drug allergies and was fully vaccinated for his age. On examination, he appeared unwell but remained conscious and oriented. Vital signs were as follows: temperature 38.8°C, heart rate 110 bpm, respiratory rate 24 breaths/minute, and oxygen saturation 94% on room air. Oropharyngeal examination revealed mild erythema of the pharynx and clear nasal secretions; tonsillar exudates were absent. Lung auscultation detected scattered rhonchi and mild wheezing bilaterally, with increased work of breathing noted. Neurological examination was unremarkable. His skin displayed the characteristic café-au-lait macules and axillary freckling associated with his NF1 diagnosis. Laboratory investigations included a positive rapid SARS-CoV-2 antigen test (nasopharyngeal swab). Influenza A and B tests were negative. The complete blood count revealed a white blood cell count of 9,000/µl with mildly depressed lymphocytes at 1,200/µl. The comprehensive metabolic panel was normal. Chest radiography showed bilateral perihilar opacities. Elevated C-reactive protein was noted at 20 mg/l.The patient was diagnosed with COVID-19 pneumonia and managed with supportive care. This included supplemental oxygen (nasal cannula) to maintain oxygen saturation >92%, intravenous fluids for hydration, and antipyretics for fever control. While the use of remdesivir was considered given his clinical presentation, it was ultimately not administered due to his rapid clinical improvement. Over the subsequent 48 hours, he showed marked clinical improvement, including resolution of his fever, improved oral intake, and increased appetite. Supplemental oxygen was discontinued on day 4. He was discharged on day 5 with instructions for rest, symptomatic treatment, and scheduled follow-up with his pediatrician.
Discussion
This case report details the clinical presentation and management of an 8-year-old with NF1 who also contracted COVID-19. The co-occurrence of these two conditions raises important questions regarding the susceptibility and potential outcomes for children with genetic disorders during the COVID-19 pandemic. NF1, a neurogenetic disorder, is characterized by the development of neurofibromas, café-au-lait spots, and a range of neurological and developmental issues. It is plausible that some children with NF1 may exhibit altered immune function, either directly related to NF1 or due to associated comorbidities [15]. Several studies reveal that immune system function can be affected by NF1, including lower levels of lymphocyte number, changes in cytokine levels, and impaired immune response [15]. While numerous studies have indicated that pre-existing genetic conditions—such as disorders involving specific gene mutations like NF1—may influence both susceptibility to COVID-19 infection and the immune response to it [16], the study by Blakeley et al. [17] reported that the presence of such underlying conditions does not significantly affect immune response. This finding contrasts with the results of our current study. However, given the still incomplete understanding of COVID-19 pathophysiology, further investigations and more precise evaluations are necessary [18]. This, in turn, could influence their vulnerability to viral infections such as SARS-CoV-2. While the patient described here experienced relatively mild respiratory symptoms consistent with COVID-19, this observation underscores the variability in disease expression among pediatric patients, even in the context of underlying genetic conditions [19].Studies have proposed various mechanisms through which the immune system may be affected in NF1. NF1 is characterized by mutations in the NF1 gene, leading to increased susceptibility to tumors of the peripheral and central nervous systems. The NF1 gene encodes neurofibromin, a negative regulator of RAS signaling; its loss results in RAS hyperactivation across multiple cell types [15]. This mutation is associated with altered immune responses, including changes in cytokine profiles and the function of mast cells, macrophages, microglia, T cells, and B cells [20]. Mouse models of NF1-related tumors have been instrumental in elucidating the link between immune dysregulation and tumor development. Notably, the involvement of mast cells, microglia, and cytokines in tumor progression has opened new avenues for targeted molecular therapies and immunotherapy [21].The existing literature generally indicates that most children experience mild to moderate symptoms of COVID-19, with severe disease being less common. However, children with pre-existing medical conditions are recognized to be at an elevated risk for complications [22]. Therefore, this case underscores the importance of heightened awareness and vigilant monitoring of pediatric patients with NF1 who contract SARS-CoV-2 infection. Although in many pediatric cases of COVID-19, the symptoms such as fever and cough are typically mild [23]. In the patient described in our study, the initial symptoms presented with greater severity. These symptoms rapidly progressed to productive cough, rhinorrhea, and lethargy. This progression may be attributed to immune system dysfunction, potentially resulting from underlying genetic mutations in the patient.These patients may benefit from tailored management strategies that address their specific health needs. Furthermore, this case adds to our growing knowledge of how COVID-19 affects children with chronic genetic conditions, highlighting the need for individualized management strategies. Healthcare professionals should be attentive to the possibility of atypical clinical presentations and complications in this population. An effective management approach often requires a multidisciplinary team working collaboratively to provide comprehensive care, including pediatricians, neurologists, and infectious disease specialists.Finally, this case reinforces the importance of COVID-19 vaccination in children with underlying health issues. Vaccination is a critical tool for reducing the risk of severe disease and hospitalization. Parents and caregivers of children with NF1 must receive thorough education regarding the benefits of vaccination, along with careful monitoring for any potential adverse effects or breakthrough infections.
Conclusion
While this patient experienced a mild COVID-19 illness, the case underscores the ongoing need for further investigation into the impact of COVID-19 on children with neurogenetic disorders such as NF1. Additional research is necessary to clarify the effects of SARS-CoV-2 in this vulnerable population and to develop targeted management guidelines for use during future pandemics.
Ethical approval
Considering the national committee for ethics in biomedical research laws. It is not necessary to obtain the Ethical Approval code for case reports; only the patient’s consent is sufficient.
Consent
Written informed consent was obtained from the patient’s parents for the publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.
References1. Wang W, Wei CJ, Cui XW, Li YH, Gu YH, Gu B, et al. Impacts of NF1 Gene mutations and genetic modifiers in neurofibromatosis type 1. Front Neurol 2021; 12:704639.2. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers 2017; 3(1):1–17.3. Haddadi K, Kargar Soleiman Abad S, Hashemie Amir SM, Pooladi M. Spinal manifestations of neurofibromatosis: an update. Iran J Neurosurg 2020; 6(4):169–80.4. Korf BR. Clinical features and pathobiology of neurofibromatosis 1. J Child Neurol 2002; 17(8):573–7; discussion 602–4, 46–51.5. Miguel CS, Chaim-Avancini TM, Silva MA, Louzã MR. Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review. Neuropsychiatr Dis Treat 2015; 11:815–21.6. Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, et al. Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations. Front Oncol 2024; 14:1323176.7. Abedi Samakoush M, Davoodi L, Khademian M, Kargar-Soleimanabad S, Abedini MA. New-onset chronic inflammatory demyelinating polyradiculoneuropathy after COVID-19 infection: a case report. Ann Med Surg (Lond) 2023; 85(10):5031–4.8. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91(1):157–60.9. Dhand R, Li J. Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med 2020; 202(5):651–9.10. Alian S, Ahangarkani F, Boskabadi SJ, Kargar-Soleimanabad S, Delavarian L, Pakzad A. Mucormycosis, one month after recovery from COVID-19: a case report. Ann Med Surg 2022; 78:103911.11. Shaikh N, Swali P, Houben R. Asymptomatic but infectious - the silent driver of pathogen transmission. A pragmatic review. Epidemics 2023; 44:100704.12. Chen H, Shi L, Zhang Y, Wang X, Jiao J, Yang M, et al. Response to the COVID-19 pandemic: comparison of strategies in six countries. Front Public Health 2021; 9:708496.13. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems. J Pers Med 2022; 12(8):1295.14. Amara SA, Díaz ED, Menon LK, Singh P, Rozanova L, Flahault A. COVID-19 outbreak management and vaccination strategy in the United States of America. Epidemiologia (Basel) 2021; 2(3):426–53.15. Karmakar S, Reilly KM. The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol 2017; 6(1):45–60.16. Mo J, Moye SL, McKay RM, Le LQ. Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene 2022; 41(9):1235–51.17. Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2–associated vestibular schwannomas. J Clin Oncol 2016; 34(14):1669–75.18. Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell 2024; 187(20):5500–29.19. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL, 2020.20. Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Lab Invest 2017; 97(2):146–57.21. Wei CJ, Gu SC, Ren JY, Gu YH, Xu XW, Chou X, et al. The impact of host immune cells on the development of neurofibromatosis type 1: the abnormal immune system provides an immune microenvironment for tumorigenesis. Neurooncol Adv 2019; 1(1):vdz037.22. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep 2022; 12(1):9950.23. Case SM, Son MB. COVID-19 in pediatrics. Rheum Dis Clin North Am 2021; 47(4):797–811
| How to Cite this Article |
| Pubmed Style Ali Ghasemi Zadeh|. Pediatric Covid-19 in a child with neurofibromatosis type 1. Case Rep Ser Med. 2025; 2(3): 45-48. doi:10.5455/CRSM.20250317092114 Web Style Ali Ghasemi Zadeh|. Pediatric Covid-19 in a child with neurofibromatosis type 1. https://www.wisdomgale.com/crsm/?mno=302657872 [Access: June 27, 2026]. doi:10.5455/CRSM.20250317092114 AMA (American Medical Association) Style Ali Ghasemi Zadeh|. Pediatric Covid-19 in a child with neurofibromatosis type 1. Case Rep Ser Med. 2025; 2(3): 45-48. doi:10.5455/CRSM.20250317092114 Vancouver/ICMJE Style Ali Ghasemi Zadeh|. Pediatric Covid-19 in a child with neurofibromatosis type 1. Case Rep Ser Med. (2025), [cited June 27, 2026]; 2(3): 45-48. doi:10.5455/CRSM.20250317092114 Harvard Style Ali Ghasemi Zadeh| (2025) Pediatric Covid-19 in a child with neurofibromatosis type 1. Case Rep Ser Med, 2 (3), 45-48. doi:10.5455/CRSM.20250317092114 Turabian Style Ali Ghasemi Zadeh|. 2025. Pediatric Covid-19 in a child with neurofibromatosis type 1. Case Reports and Series in Medicine, 2 (3), 45-48. doi:10.5455/CRSM.20250317092114 Chicago Style Ali Ghasemi Zadeh|. "Pediatric Covid-19 in a child with neurofibromatosis type 1." Case Reports and Series in Medicine 2 (2025), 45-48. doi:10.5455/CRSM.20250317092114 MLA (The Modern Language Association) Style Ali Ghasemi Zadeh|. "Pediatric Covid-19 in a child with neurofibromatosis type 1." Case Reports and Series in Medicine 2.3 (2025), 45-48. Print. doi:10.5455/CRSM.20250317092114 APA (American Psychological Association) Style Ali Ghasemi Zadeh| (2025) Pediatric Covid-19 in a child with neurofibromatosis type 1. Case Reports and Series in Medicine, 2 (3), 45-48. doi:10.5455/CRSM.20250317092114 |


